Akebia Therapeutics (AKBA) Total Debt: 2018-2025
Historic Total Debt for Akebia Therapeutics (AKBA) over the last 6 years, with Sep 2025 value amounting to $47.6 million.
- Akebia Therapeutics' Total Debt rose 24.21% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 24.21%. This contributed to the annual value of $38.7 million for FY2024, which is 11.56% up from last year.
- Per Akebia Therapeutics' latest filing, its Total Debt stood at $47.6 million for Q3 2025, which was up 1.23% from $47.1 million recorded in Q2 2025.
- Akebia Therapeutics' 5-year Total Debt high stood at $98.2 million for Q2 2022, and its period low was $30.1 million during Q1 2024.
- Over the past 3 years, Akebia Therapeutics' median Total Debt value was $42.5 million (recorded in 2023), while the average stood at $41.5 million.
- As far as peak fluctuations go, Akebia Therapeutics' Total Debt tumbled by 56.72% in 2023, and later skyrocketed by 54.29% in 2025.
- Akebia Therapeutics' Total Debt (Quarterly) stood at $97.5 million in 2021, then plummeted by 32.26% to $66.1 million in 2022, then slumped by 47.51% to $34.7 million in 2023, then rose by 11.56% to $38.7 million in 2024, then climbed by 24.21% to $47.6 million in 2025.
- Its last three reported values are $47.6 million in Q3 2025, $47.1 million for Q2 2025, and $46.5 million during Q1 2025.